CTR-Art.1 | Scope (Article 1) | 0 |
CTR-Art.10 | Specific considerations for vulnerable populations (Article 10) | 1 |
CTR-Art.15_16_17 | Substantial modification procedure (Articles 15-17) | 1 |
CTR-Art.2 | Definitions (Article 2) | 0 |
CTR-Art.25_26_27 | Application dossier and language requirements (Articles 25-27) | 1 |
CTR-Art.28 | General rules on subject protection (Article 28) | 4 |
CTR-Art.29 | Informed consent (Article 29) | 3 |
CTR-Art.3 | General principle (Article 3) | 1 |
CTR-Art.31_32 | Trials on incapacitated subjects and minors (Articles 31-32) | 1 |
CTR-Art.33_34_35 | Pregnant/breastfeeding subjects, additional national measures, emergency trials (Articles 33-35) | 1 |
CTR-Art.36_37 | Start and end of trial notifications (Articles 36-37) | 1 |
CTR-Art.38 | Temporary halt or early termination for subject safety (Article 38) | 1 |
CTR-Art.41_42 | Adverse-event and SUSAR reporting (Articles 41-42) | 3 |
CTR-Art.43 | Annual safety reporting (Article 43) | 1 |
CTR-Art.47 | Compliance with the protocol and Good Clinical Practice (Article 47) | 1 |
CTR-Art.48 | Monitoring (Article 48) | 1 |
CTR-Art.4_5 | Prior authorisation and submission of application (Articles 4-5) | 1 |
CTR-Art.52 | Reporting of serious breaches (Article 52) | 1 |
CTR-Art.57_58 | Clinical trial master file and archiving (Articles 57-58) | 1 |
CTR-Art.61_62_63 | Manufacturing and import of IMPs and the qualified person (Articles 61-63) | 1 |
CTR-Art.66_67_68_69 | Labelling of investigational medicinal products (Articles 66-69) | 1 |
CTR-Art.6_7 | Part I and Part II assessment (Articles 6-7) | 0 |
CTR-Art.71_72_73_74 | Sponsor, co-sponsorship, principal investigator and legal representative (Articles 71-74) | 1 |
CTR-Art.76 | Damage compensation (Article 76) | 0 |
CTR-Art.77_78_79 | Corrective measures, Member State inspections and Union controls (Articles 77-79) | 0 |
CTR-Art.8 | Decision on the clinical trial (Article 8) | 0 |
CTR-Art.80_81_82 | EU portal, EU database and functionality (Articles 80-82) - CTIS | 2 |
CTR-Art.83_84_85 | National contact points, Agency support and Clinical Trials Coordination and Advisory Group (Articles 83-85) | 0 |
CTR-Art.93 | Data protection (Article 93) | 1 |
CTR-Art.94 | Penalties (Article 94) | 0 |